TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) › Gross ProfitTEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) — Gross ProfitAnnual figures by period end, from SEC filings.2007-12-31: $4.88B2008-12-31: $5.97B2009-12-31: $7.37B2010-12-31: $9.06B2011-12-31: $9.52B2012-12-31: $10.65B2013-12-31: $10.71B2016-12-31: $11.65B2017-12-31: $10.62B2018-12-31: $8.30B2019-12-31: $7.54B2020-12-31: $7.73B2021-12-31: $7.59B2022-12-31: $6.97B2023-12-31: $7.64B2024-12-31: $8.06B2025-12-31: $8.94B$8.94B2007-12-31Gross Profit (USD)2025-12-31Period endedGross ProfitChange YoYSource filing2025-12-31$8.94B+10.8%2026-02-03From 2025-01-012024-12-31$8.06B+5.5%2026-02-03From 2024-01-012023-12-31$7.64B+9.6%2026-02-03From 2023-01-012022-12-31$6.97B-8.2%2025-02-05From 2022-01-012021-12-31$7.59B-1.7%2024-02-12From 2021-01-012020-12-31$7.73B+2.5%2023-02-10From 2020-01-012019-12-31$7.54B-9.1%2022-02-09From 2019-01-012018-12-31$8.30B-21.8%2021-02-10From 2018-01-012017-12-31$10.62B-8.9%2020-02-21From 2017-01-012016-12-31$11.65B—2019-02-19From 2016-01-072013-12-31$10.71B+0.5%2014-02-10From 2013-01-012012-12-31$10.65B+11.9%2014-02-10From 2012-01-012011-12-31$9.52B+5.0%2014-02-10From 2011-01-012010-12-31$9.06B+23.0%2013-02-12From 2010-01-012009-12-31$7.37B+23.4%2012-02-17From 2009-01-012008-12-31$5.97B+22.4%2011-02-15From 2008-01-012007-12-31$4.88B—2010-02-22From 2007-01-01Other metrics: RevenueCost of RevenueOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)